MannKind Reviews

16 Reviews
16 Reviews
Rating Trends

Recommend to a friend
Approve of CEO
MannKind Chairman and CEO Alfred E. Mann
Alfred E. Mann
14 Ratings

    Great People, Great Product. Great Future?

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    • Career Opportunities
    Former Employee - Anonymous
    Former Employee - Anonymous

    I worked at MannKind full-time (more than 5 years)


    Working at MannKind provided an opportunity to collaborate on projects at a high level with some of the most talented and dedicated people I have ever met. The relationships among coworkers were unusually strong and supportive. Taking initiative was encouraged, recognized and rewarded. Compensation and benefits were better than most start-up companies. The flexible work hours significantly increased my productivity. The Company's lead product (AFREZZA) and its underlying technology (Technosphere) have enormous medical value and market potential.


    Company-wide communications provided important information and a sense of transparency. We believed that our ideas and recommendations were genuinely valued and taken into serious consideration. However, it seemed as though crucial decisions were made within an executive "bubble" which severely impacted operations and lead to substantial layoffs of highly valuable employees.

    Advice to ManagementAdvice

    If it is not too late, try to return to the core principles which made the company a great place to work.

    Neutral Outlook
    Approves of CEO

MannKind Awards and Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Headquarters Valencia, CA
Size 150 to 499 Employees
Founded 1991
Type Company - Public (MNKD)
Industry Biotech & Pharmaceuticals
Revenue Less than £1 million (GBP) per year

With a name like MannKind, what can you do but attempt to improve the well-being of mankind? The biopharmaceutical company focuses on developing and commercializing therapeutic products to treat diabetes and cancer. Its lead product candidate, AFREZZA, uses its Technosphere inhalation system technology to treat type 2 diabetes. The system consists of a special inhaler that releases deep into the lungs a formula of dry powder insulin that could raise insulin levels more quickly and with less discomfort than other methods. The company is also developing therapeutic cancer... More

Work at MannKind? Share Your Experiences


Click to Rate